Digital Biomarkers: A New Dawn in CNS R&D

The CNS drug field has been hampered by trial failures in areas of substantial unmet medical need. In addition, given the heterogeneous nature of the targeted patient population, the prescribing of drugs best suited to said sub-population of patients is challenging, which results in poor response rates to many CNS medications.
Digital biomarkers promise not only to improve early stage diagnosis of CNS disorders, but also to have a major impact on CNS drug discovery and development, and ultimately, patient compliance and assessment. This session will discuss how a stratified medicine approach using proprietary digital biomarkers optimised using AI/ML techniques could discover and validate new targets, as well as significantly reduce the risk of late-stage failure.